Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia

Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Barth, Brian M., Wang, Weiyuan, Toran, Paul T., Fox, Todd E., Annageldiyev, Charyguly, Ondrasik, Regina M., Keasey, Nicole R., Brown, Timothy J., Devine, Viola G., Sullivan, Emily C., Cote, Andrea L., Papakotsi, Vasiliki, Tan, Su-Fern, Shanmugavelandy, Sriram S., Deering, Tye G., Needle, David B., Stern, Stephan T., Zhu, Junjia, Liao, Jason, Viny, Aaron D., Feith, David J., Levine, Ross L., Wang, Hong-Gang, Loughran, Thomas P., Sharma, Arati, Kester, Mark, Claxton, David F.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Stimulus Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737412/
https://ncbi.nlm.nih.gov/pubmed/31488436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018021295
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars